Immatics Appoints Cedrik Britten as Chief Medical Officer
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T c…
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T c…
Clinical study demonstrates proof-of-concept for active personalized immunotherapy approach in a pioneering multi-center…
The prospect of an actively personalized approach to the treatment of glioblastoma has moved a step closer with the rece…
. - Regulatory authority approves clinical trial for Glioma Actively Personalized Vaccine Consortium (GAPVAC) - First…
. - Projekt wird gemeinsam von den Biotechnologiefirmen immatics (Tübingen) und BioNTech (Mainz) geleitet - Regulator…
. - Glioma Actively Personalized Vaccine Consortium (GAPVAC): 14 organizations in Europe and the US join forces to deve…
. - Glioma Actively Personalized Vaccine Consortium (GAPVAC): 14 Institutionen aus Europa und den USA entwickeln einen…